Stockscreener 앱 받기
4.56
2.47%
0.11
시간 외 거래:
4.61
0.05
+1.10%
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
TSHA: Analyst Chardan Capital Maintains Buy Rating with $12 PT | - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Australia
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlight - GuruFocus
Taysha Gene Therapies, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies’ Q4 Earnings Call: FDA Timeline, European Strategy Claims Don’t Match Prior Statements - Bitget
Taysha (TSHA) Reports Strong Q4 Revenue and Promising Progress i - GuruFocus
Taysha Gene Therapies Q4 Earnings Call Highlights - Yahoo Finance
Taysha Gene Therapies 2026 Conference Call: TSHA-102 Development & Regulatory PlansNews and Statistics - IndexBox
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update - Investing News Network
TSHA: TSHA-102 advanced toward registration with strong trial data, FDA alignment, and solid cash runway - TradingView
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Taysha (TSHA) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Taysha (TSHA) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Taysha Gene Therapies Q4 2025 sees widened loss - Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Valuation Update: How correlated is Taysha Gene Therapies Inc to the S P5002026 Price Momentum & Daily Oversold Bounce Ideas - baoquankhu1.vn
Taysha Gene Therapies, Inc. Appoints Brad Martin as Senior Vice President, Market Access and Value - marketscreener.com
Taysha (TSHA) Reports Strong Q4 Revenue and Promising Progress in Trials - GuruFocus
Taysha Gene Therapies 10-K: $9.8M Revenue, $(0.34) EPS - TradingView
Rett gene therapy advances at Taysha Gene Therapies (TSHA) - Stock Titan
Taysha Gene Therapies reports full-year 2025 earnings and issues corporate update - Traders Union
Earnings Flash (TSHA) Taysha Gene Therapies Posts 2025 Net Loss $0.34 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Taysha Gene Therap Reports 2025 Full-Year Results — $9.8M Revenue, $109.0M Net Loss - TradingView
Taysha Gene Therapies (TSHA) deepens 2025 loss but advances Rett trial - Stock Titan
TSHA: TSHA-102 trials progressed with strong safety, regulatory alignment, and robust cash position - TradingView
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Needham Maintains Taysha Gene Therapies (TSHA) Buy Recommendation - MSN
Ally Bridge Group NY LLC Acquires Shares of 1,898,112 Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19 - The Manila Times
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade - MSN
Jefferies Financial Group Inc. Sells 8,157,091 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
B of A Securities Initiates Coverage of Taysha Gene Therapies (TSHA) with Buy Recommendation - MSN
Aug Catalysts: How cyclical is Taysha Gene Therapies Incs revenue streamDividend Hike & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug Reactions: What hedge funds are buying Taysha Gene Therapies IncTrade Risk Report & Weekly Hot Stock Watchlists - baoquankhu1.vn
Decliners Report: Is Taysha Gene Therapies Inc stock good for income investors2025 Winners & Losers & Weekly Top Performers Watchlists - baoquankhu1.vn
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies (TSHA) Grants Stock Units and Options to N - GuruFocus
Taysha Gene Therapies announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
New Taysha hire granted 156,870 RSUs plus 134,460 options - Stock Titan
Highs Report: Is Taysha Gene Therapies Inc attractive for institutional investorsTrade Entry Summary & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Aug Update: Will Taysha Gene Therapies Inc benefit from AI trendsJuly 2025 Recap & Fast Gain Swing Trade Alerts - baoquankhu1.vn
TSHA SEC FilingsTaysha Gene Therapies, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Taysha Gene Therapies (TSHA) and Zimmer Biomet Holdings (ZBH) - The Globe and Mail
TSHA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Taysha Gene faces earnings test as Rett trial advances By Investing.com - Investing.com Nigeria
Taysha Gene faces earnings test as Rett trial advances - Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Needham & Company LLC - MarketBeat
TSHA: Needham Reiterates Buy Rating with Price Target Maintained - GuruFocus
TSHA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Taysha Gene Therapies, Inc. (TSHA): Analyst Ratings Signal Potential 140% Upside In Biotech Stock - DirectorsTalk Interviews
Insider sale activity at Taysha Gene Therapies (NASDAQ: TSHA) - Stock Titan
What is the next catalyst for Taysha Gene Therapies Inc.Long Setup & Precise Buy Zone Identification - mfd.ru
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Taysha Gene Therapies Inc. benefit from AI trendsTrade Entry Summary & Detailed Earnings Play Alerts - mfd.ru
How liquid is Taysha Gene Therapies Inc. stock2025 Breakouts & Breakdowns & Technical Pattern Alert System - mfd.ru
RTW INVESTMENTS, LP Reduces Stake in Taysha Gene Therapies Inc - GuruFocus
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Unpacking a 129.65% Potential Upside - DirectorsTalk Interviews
Analysts Offer Insights on Healthcare Companies: OrganiGram Holdings (OGI), Taysha Gene Therapies (TSHA) and BioRestorative Therapies (BRTX) - The Globe and Mail
Needham Reiterates Taysha Gene Therapies (TSHA) Buy Recommendation - MSN
GSA Capital Partners LLP Increases Holdings in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies (TSHA) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):